

**Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan**

***The Board of Directors of MolMed exercises the power to increase the share capital up to a maximum amount of Euro 50 million***

Milan (Italy), 23 February 2015 – The Board of Directors of MolMed S.p.A. (“MolMed” or the “Company”) held today resolved to exercise the power, granted to it pursuant to Article 2443 of the Italian Civil Code by the Extraordinary Shareholders’ Meeting held on 3 March 2014, to increase the share capital against payment and in divisible form, also in more tranches by and no later than 31 May 2015, for an aggregate maximum amount equal to Euro 50 million, including the relevant share premium, to be executed through the issuance of ordinary shares with no par value, regular entitlement and having the same characteristics of the currently outstanding shares of the Company, to be offered with pre-emptive rights to the shareholders of the Company pursuant to Article 2441, paragraph 1 of the Italian Civil Code (the “Rights Issue”).

The final terms of the Rights Issue, such as the subscription price of the newly issued shares, the actual number of shares to be issued and the relevant option ratio, shall be determined by the Board of Directors in a meeting to be called in the days immediately preceding the commencement of the offer period, at the moment foreseen for March, subject to release of the necessary authorization requested by law.

In the wide context of financial strengthening carried out by the Company, the Rights Issue will permit to gather further financial resources to allow the full implementation of the development plans of the Company.

The shareholders H-Equity and H-Invest have expressed their intent to subscribe for the Rights Issue in proportion to their respective shareholdings and, in such respect, have paid the residual amount of their financial support commitments entered into on 31 January 2014.

The shareholder Airain has notified the Company of its intent to subscribe for the Rights Issue in proportion to its shareholding thereby satisfying its residual commitment of financial support entered into on 31 January 2014.

Furthermore please consider that in September 2014, the Shareholder Fininvest has paid the residual amount of its financial support commitment entered into on 31 January 2014 as an advance on future capital increase.

---

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

***About MolMed***

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two anti-tumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate

**FROM GENES TO THERAPY**

---

**MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325  
info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



**Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan**

projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

***For further information:***

**Marina Del Bue**

**General Manager Business & Administration  
Investor Relations Director *ad int.***

MolMed S.p.A.  
phone: +39 02 21277.371  
fax: +39 02 21277.325  
e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Andrea Quaglino**

**Director of Administration, Finance and Control**

MolMed S.p.A.  
phone: +39 02 21277.302  
fax: +39 02 21277.404  
e-mail: [afc@molmed.com](mailto:afc@molmed.com)

**Press agent**

**Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali srl  
phone: +39 02 6249991 – mobile +39 347 6456873  
e-mail: [ferrari@secrp.it](mailto:ferrari@secrp.it)

**DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.*